NEW YORK – Mesa Biotech has entered the clinical validation stage of a molecular diagnostic test for SARS-CoV-2, the virus that causes coronavirus disease COVID-19. The test runs on the firm's handheld system, which is already CLIA waived in the US for influenza testing.
The test is currently being clinically validated in collaboration with researchers at the coronavirus reference laboratory at the Centers for Disease Control in China, the firm's CEO, Hong Cai, said in an interview.